Ming‐Shen Dai

1.8k citations
71 papers · 771 indexed · h-index 17
Topics
HER2/EGFR in Cancer Research (9 papers)Cancer Treatment and Pharmacology (9 papers)Advanced Breast Cancer Therapies (7 papers)
Journals
Nature MedicineJournal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations
TaiwanUnited StatesChina

In The Last Decade

Ming‐Shen Dai

66 papers receiving 755 citations

Peers

Ming‐Shen Dai
Comparison fields: 5 of 96
  • Oncology 278
  • Molecular Biology 206
  • Pulmonary and Respiratory Medicine 171
  • Cancer Research 94
  • Epidemiology 83
Replace Frank Meiß with:
Frank Meiß Germany
Michaëla Semeraro France
Stephan Haas Sweden
Pingting Zhou China
S Traoré Burkina Faso
Bogdan Cylwik Poland
Maria Vadiaka Greece
Jing Cui China
Tingting Liu China
Shulin Yu China
Ming‐Shen Dai relative to Frank Meiß Germany Frank Meiß's profile →
Citations per field
00.5×1.6×
Frank Meiß · 1×
Citations per year

Countries citing papers authored by Ming‐Shen Dai

Since Specialization
Citations

This map shows the geographic impact of Ming‐Shen Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Shen Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Shen Dai more than expected).

Fields of papers citing papers by Ming‐Shen Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Shen Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Shen Dai. The network helps show where Ming‐Shen Dai may publish in the future.

Co-authorship network of co-authors of Ming‐Shen Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Shen Dai. A scholar is included among the top collaborators of Ming‐Shen Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Shen Dai. Ming‐Shen Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 19
3 5
4 11
5 11
6 2
7 2
8 17
9 20
10 7
11 5
12 10
13 1
14 28
15 7
16 0
17 3
18 9
19 4
20 55

About Ming‐Shen Dai

Ming‐Shen Dai is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine, having authored 71 papers that have together received 771 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (7 papers). The work is most often cited by research in Biological Psychiatry (26 citations), Oncology (278 citations) and Hepatology (52 citations). Ming‐Shen Dai has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Ching‐Liang Ho, Yuguang Chen, Jyh‐Cherng Yu, Ping‐Ying Chang, Tsu‐Yi Chao, Guo‐Shiou Liao, Chia‐Hung Kao, Cheng‐Li Lin, Huan-Ming Hsu and Te‐Yu Lin. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026